Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02408120 · ClinicalTrials.gov registry record · Phase 4
Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes
A Phase 4 study of Diabetes Mellitus, Type 2, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 226
- Enrollment target
- 2
- Study locations
NCT02408120: Completed Phase 4 study of Diabetes Mellitus, Type 2, sponsored by Emory University.
NCT02408120 is a Phase 4 study of Diabetes Mellitus, Type 2 that has completed, run by Emory University. The registered enrollment target is 226 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02408120, a Phase 4 study of Diabetes Mellitus, Type 2, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 226 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test whether using extra doses of aspart insulin to correct blood sugars before meals improves the care of patients with type 2 diabetes in the hospital who are already receiving the standard of care treatment with glargine and aspart insulin injections to control blood sugar levels. Studies done in the past indicate that blood sugar levels are controlled on the standard treatment of insulin and that most patients do not need the small extra dose of insulin at bedtime. The investigators want to test if there is any benefit to giving patients extra doses of insulin during the day to correct the high blood sugars.
Primary Outcome
Blood glucose (BG) will be measured, and mean daily BG levels will be calculated.
Conditions Studied
Interventions
- DRUG Insulin aspart
- DRUG Insulin glargine
- DRUG Supplemental insulin aspart
Study Locations (2)
Georgia
- Grady Memorial Hospital - Atlanta
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 4 |
What the finished NCT02408120 record still lists
NCT02408120 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Insulin aspart is the first listed.
NCT02408120 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT02408120 about?
NCT02408120 is a clinical study titled "Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes". The purpose of this study is to test whether using extra doses of aspart insulin to correct blood sugars before meals improves the care of patients with type 2 diabetes in the hospital who are already receiving the standard of care treatment with glargine and aspart insulin injections to control blo...
What is the current status of trial NCT02408120?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 226 participants. The study started on 2015-10. Estimated completion is 2019-12-11.
What conditions does trial NCT02408120 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT02408120?
The interventions under investigation include: Insulin aspart (DRUG), Insulin glargine (DRUG), Supplemental insulin aspart (DRUG).
Who is sponsoring clinical trial NCT02408120?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02408120 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02408120's enrollment target sits among peer trials
226 142nd of 348 higher than 206 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
Effect of Continuing Versus Holding Metformin During Hospitalizations.
RECRUITING · Phase 4
-
Surgical or Medical Treatment
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Effect of Thiazolidinedione Treatment Vascular Risk Markers
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia